Catalyst Wire Dossier Catalyst Wire Dossier

TALEN and CRISPR/Cas9 gene-editing therapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TALEN and CRISPR/Cas9 gene-editing therapy, covering 2017-06-09 to 2017-06-09. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ [Phase 1]

See pricing